The National Cancer Institute (NCI) has named International Aspirin Foundation’s Scientific Advisory Board member Andrew Chan MD MPH one of the 2020 recipients of its prestigious Outstanding Investigator Award (OIA).
The NCI OIA is one of the most highly regarded research awards available to cancer investigators in the USA. The highly competitive award supports accomplished leaders in cancer research with outstanding records of productivity and who are contributing significantly toward understanding cancer and developing applications that may lead to a breakthrough in biomedical, behavioral, or clinical cancer research. The OIA provides extended funding stability to encourage investigators to continue or embark on projects of unusual potential in cancer research.
Dr Chan will receive over $7 million dollars over the next 7 years to support his work.
Dr Chan said: “I am deeply honoured and grateful to receive this recognition from the NCI. The funding support will support our efforts to develop precision cancer prevention strategies with aspirin and other potential interventions”.
Dr Chan is Chief of the Clinical and Translational Epidemiology Unit in the Department of Medicine and Director of Epidemiology at the Cancer Center at Massachusetts General Hospital, Boston, and Co-leader of the Cancer Epidemiology Program at the Dana-Farber/Harvard Cancer Center, Boston. His work has already been recognised with many awards, including the American Association for Cancer Research, Waun Ki Hong Award for Excellence in Translational and Clinical Cancer Research. He has been a member of the International Aspirin Foundation’s Scientific Advisory Board since 2015.
Professor Carlo Patrono, MD, FESC, FRCP, Chair of the International Aspirin Foundation’s Scientific Advisory Board said: “I am delighted to hear that Andy’s work has been recognised with this prestigious award and offer him warmest congratulations on behalf of everyone at The Foundation. Andy’s work is inspiring and important because it integrates rigorous epidemiological research with molecular and genetic mechanistic studies of cancer chemoprevention, and we are extremely proud to have him working on our Scientific Advisory Board”.
For further details contact Pippa Hutchison, Executive Director, International Aspirin Foundation